YouTube’s Dr. Dan on GLP-1s: The Science, Myths, and Future of Weight Loss Medications P1 Artwork

The Plus SideZ: A Guide to GLP-1 & Metabolic Health

Looking for real information on GLP-1 medications and weight loss? You’re in the right place.

The Plus SideZ Podcast is your go-to space for science-backed conversations about obesity treatment, weight loss, and living with a chronic metabolic disorder. Hosted by Kim Carlos and Kat Carter, we explore GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound, featuring insights from leading obesity specialists, endocrinologists, and bariatric surgeons. But this podcast is about more than just medication—it’s about navigating the mental, emotional, and physical journey of reclaiming your health.

We combat misinformation with education from top experts, helping you think critically about the latest research, treatment options, and systemic challenges in obesity care. And at the heart of it all are the powerful, vulnerable stories of our brave community members—people sharing their real experiences on GLP-1 medications, breaking stigma, and taking control of their health.

Ranked in the top 1% of podcasts globally, The Plus SideZ Podcast has won three awards in just 18 months, including two Anthem Awards for social impact. Featured on Good Morning America, Bloomberg News, and ABC Nightline on Hulu, we’re at the forefront of the conversation on weight loss, obesity care, and the fight to end weight bias.

Join us and be part of a movement that’s changing the way the world understands obesity, health, and metabolic wellness.

Our Linktree

https://linktr.ee/theplussidez

Want to donate?

PayPal
https://www.paypal.com/donate/?hosted_button_id=ZSEE2DRPHDSZN

GoFundMe
https://gofund.me/82c8138e

Shop The Plus SideZ Merch Store
https://the-plus-sidez-podcast.printify.me/products/1

Website
https://theplussidez.com/

All Episodes

The Plus SideZ: A Guide to GLP-1 & Metabolic Health

YouTube’s Dr. Dan on GLP-1s: The Science, Myths, and Future of Weight Loss Medications P1

October 13, 2025 • Season 5 • Episode 18

Resources for the Community:

________________________________________________________________

https://linktr.ee/theplussidezpodcast

Ro - Telehealth for GLP1 weight management

https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55

______________________________________________________________________

This isn’t medical advice — always talk to your doctor before making any health decisions.

In this episode, we sit down with Dr. Dan, a pharmacist and expert in Obesity Medicine, to unpack the science and future of the new generation of weight loss medications.

We unpack the basics, like what is insulin resistance? Dr. Dan explains how GLP-1 medications effectively treat this core metabolic dysfunction and why their multi-hormonal action provides superior, sustained results compared to older weight loss drugs. He also delves into the age-related changes in metabolism that make weight management challenging.

Dr Dan tackles some obesity and GLP1 myths with us as well. He debunks the popular and potentially harmful myth of "cycling GLP-1s" to prevent "receptor damage,". He emphaszies how obesity is a chronic disease that needs consistent treatment. Following this, we explore real-world strategies for weight loss maintenance, discussing the different treatment scenarios he sees in his practice.

Finally, we look ahead to the future: understanding the next wave of pipeline GLP-1s and current studies on higher doses. Dr. Dan discusses combined therapies as patients get further into their health and wellness journey.

Community Guest:

Lorri

@Glpjourneyinreview

Professional Guest:

Dr. Dan

@theofficialdrdan

Dr. Dan's Empowerment Hub - https://drdans-empowermenthub.mn.co/share/KQA8wVMb6pOc5R79?utm_source=manual

______________________________________________________________________

⭐️Mounjaro Stanley⭐️

griffintumblerco.Etsy.com

Use code PODCAST10 for $ OFF

______________________________________________________________________